Finerenone Cuts Cardiorenal Risk 23% in Nondiabetic CKD, Slowing eGFR Decline by 0.7
Finerenone Reduces Kidney Decline and Cardiovascular Risk in Nondiabetic CKD PatientsFinerenone Kidney Drug Shows Broad Efficacy, Reducing Kidney Failure, Heart Failure, and Death RisksFinerenone Kidney Drug Shown to Protect Heart and Kidneys in Millions More Patients After Three Major 2026 StudiesBreakthrough for 800 Million Patients? Kidney Disease Drug Shows Powerful New BenefitsFinerenone in Persons with Chronic Kidney Disease without Diabetes | New England Journal of MedicineA drug currently approved for chronic kidney disease (CKD) linked with type 2 diabetes (T2D), called Finerenone, has expanded use, highlighting chronic kidney disease care, kidney protection, #cardiovascular health, targeted therapy, andFDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD | HCPLiveThe effect of dapagliflozin ( DAPA ) , finerenone ( FINE ) and their... | Download Scientific Diagram